Lace up with #TeamAscidian for the fightblindness.bsky.social Boston VisionWalk on Sat Oct 3! 👟 🦮
Together, we're taking important steps toward a brighter future.
🔗 tinyurl.com/mr32s5bh
#VisionWalkStrong #StargardtDisease #STELLAR #STARPATH
Together, we're taking important steps toward a brighter future.
🔗 tinyurl.com/mr32s5bh
#VisionWalkStrong #StargardtDisease #STELLAR #STARPATH
September 30, 2026 at 3:15 PM
Lace up with #TeamAscidian for the fightblindness.bsky.social Boston VisionWalk on Sat Oct 3! 👟 🦮
Together, we're taking important steps toward a brighter future.
🔗 tinyurl.com/mr32s5bh
#VisionWalkStrong #StargardtDisease #STELLAR #STARPATH
Together, we're taking important steps toward a brighter future.
🔗 tinyurl.com/mr32s5bh
#VisionWalkStrong #StargardtDisease #STELLAR #STARPATH
Our Bluesky debut! 🚀 This weekend, we joined leading retinal disease research experts at the RD Fund Investing in Cures Summit, where our CSO Robert Bell shared insights on #RNAExonEditing & #StargardtDisease. Grateful for @fightblindness.bsky.social’s leadership in this space! #biosky
March 24, 2025 at 3:53 PM
Our Bluesky debut! 🚀 This weekend, we joined leading retinal disease research experts at the RD Fund Investing in Cures Summit, where our CSO Robert Bell shared insights on #RNAExonEditing & #StargardtDisease. Grateful for @fightblindness.bsky.social’s leadership in this space! #biosky
We’re thrilled to welcome Dr. Murray A. Abramson as Chief Development Officer & announce our new Ophthalmology Clinical Advisory Board guiding ACDN-01 for #StargardtDisease. Big things ahead!
🔗 ascidian-tx.com/press-releas...
#RNAExonEditing #TeamAscidian #Biosky
🔗 ascidian-tx.com/press-releas...
#RNAExonEditing #TeamAscidian #Biosky
June 24, 2025 at 11:31 AM
We’re thrilled to welcome Dr. Murray A. Abramson as Chief Development Officer & announce our new Ophthalmology Clinical Advisory Board guiding ACDN-01 for #StargardtDisease. Big things ahead!
🔗 ascidian-tx.com/press-releas...
#RNAExonEditing #TeamAscidian #Biosky
🔗 ascidian-tx.com/press-releas...
#RNAExonEditing #TeamAscidian #Biosky
On #RareDiseaseDay, learn how Ascidian is working to rewrite the story of #StargardtDisease. See and hear🎶 how our RNA exon editors work ⬇️
Then explore our Phase 1/2 STELLAR clinical trial and our STARPATH prescreening study: 🔗 stellarstargardttrial.com
Then explore our Phase 1/2 STELLAR clinical trial and our STARPATH prescreening study: 🔗 stellarstargardttrial.com
February 27, 2026 at 2:47 PM
On #RareDiseaseDay, learn how Ascidian is working to rewrite the story of #StargardtDisease. See and hear🎶 how our RNA exon editors work ⬇️
Then explore our Phase 1/2 STELLAR clinical trial and our STARPATH prescreening study: 🔗 stellarstargardttrial.com
Then explore our Phase 1/2 STELLAR clinical trial and our STARPATH prescreening study: 🔗 stellarstargardttrial.com
#PortfolioNews | Proud to join the $135M Series B of our #portfolio company #SpliceBio, the largest round ever raised by a Spanish biotech 🚀
🧬 Advance SB-007 for #StargardtDisease
🔬Expand #GeneticMedicine pipeline
👉 buff.ly/jey8g9O
#VC #Biotech #Innovation #ProteinSplicing
🧬 Advance SB-007 for #StargardtDisease
🔬Expand #GeneticMedicine pipeline
👉 buff.ly/jey8g9O
#VC #Biotech #Innovation #ProteinSplicing
June 11, 2025 at 9:16 AM
#PortfolioNews | Proud to join the $135M Series B of our #portfolio company #SpliceBio, the largest round ever raised by a Spanish biotech 🚀
🧬 Advance SB-007 for #StargardtDisease
🔬Expand #GeneticMedicine pipeline
👉 buff.ly/jey8g9O
#VC #Biotech #Innovation #ProteinSplicing
🧬 Advance SB-007 for #StargardtDisease
🔬Expand #GeneticMedicine pipeline
👉 buff.ly/jey8g9O
#VC #Biotech #Innovation #ProteinSplicing
As #BlindnessAwarenessMonth wraps up, check out Bradford Manning’s must-see master class on #StargardtDisease, which launched last year. We’re grateful to have been part of it: bit.ly/3yB9trX. #ShareYourVision
October 31, 2025 at 12:15 PM
As #BlindnessAwarenessMonth wraps up, check out Bradford Manning’s must-see master class on #StargardtDisease, which launched last year. We’re grateful to have been part of it: bit.ly/3yB9trX. #ShareYourVision
📽️ Partnership Perspectives | #6 of 6
Ascidian isn’t just editing RNA, we’re rewriting what's possible — in #StargardtDisease, neurological disorders, kidney disease, and more.
CEO Michael Ehlers on how Ascidian is meeting the moment🚀
Ascidian isn’t just editing RNA, we’re rewriting what's possible — in #StargardtDisease, neurological disorders, kidney disease, and more.
CEO Michael Ehlers on how Ascidian is meeting the moment🚀
June 25, 2026 at 12:27 PM
📽️ Partnership Perspectives | #6 of 6
Ascidian isn’t just editing RNA, we’re rewriting what's possible — in #StargardtDisease, neurological disorders, kidney disease, and more.
CEO Michael Ehlers on how Ascidian is meeting the moment🚀
Ascidian isn’t just editing RNA, we’re rewriting what's possible — in #StargardtDisease, neurological disorders, kidney disease, and more.
CEO Michael Ehlers on how Ascidian is meeting the moment🚀
Attending #ASGCT2026?
Ascidian CDO Murray Abramson, MD, MPH, is presenting first-in-human safety data for #ACDN-01 in #StargardtDisease.
⏰ Today, 3:45-4:00 PM
📍 Room 258ABC (Level 2), Thomas M. Menino Convention & Exhibit Center
Ascidian CDO Murray Abramson, MD, MPH, is presenting first-in-human safety data for #ACDN-01 in #StargardtDisease.
⏰ Today, 3:45-4:00 PM
📍 Room 258ABC (Level 2), Thomas M. Menino Convention & Exhibit Center
May 12, 2026 at 2:54 PM
Attending #ASGCT2026?
Ascidian CDO Murray Abramson, MD, MPH, is presenting first-in-human safety data for #ACDN-01 in #StargardtDisease.
⏰ Today, 3:45-4:00 PM
📍 Room 258ABC (Level 2), Thomas M. Menino Convention & Exhibit Center
Ascidian CDO Murray Abramson, MD, MPH, is presenting first-in-human safety data for #ACDN-01 in #StargardtDisease.
⏰ Today, 3:45-4:00 PM
📍 Room 258ABC (Level 2), Thomas M. Menino Convention & Exhibit Center
Clinical milestones for ACDN-01 in #StargardtDisease: dose escalation complete in the STELLAR trial with pediatric expansion underway, and new STARPATH prescreening study now enrolling adult and pediatric patients.
Full details 🔗 ascidian-tx.com/wp-content/u...
Full details 🔗 ascidian-tx.com/wp-content/u...
May 4, 2026 at 1:02 PM
Clinical milestones for ACDN-01 in #StargardtDisease: dose escalation complete in the STELLAR trial with pediatric expansion underway, and new STARPATH prescreening study now enrolling adult and pediatric patients.
Full details 🔗 ascidian-tx.com/wp-content/u...
Full details 🔗 ascidian-tx.com/wp-content/u...
#PortfolioNews | SpliceBio doses the first patient in the Phase 1/2 ASTRA study of SB-007, the first dual AAV #GeneTherapy for #StargardtDisease!
🎯 Showcasing the power of #ProteinSplicing to tackle diseases caused by #LargeGenes mutations.
👉 buff.ly/HvB3bPR
#VC
🎯 Showcasing the power of #ProteinSplicing to tackle diseases caused by #LargeGenes mutations.
👉 buff.ly/HvB3bPR
#VC
March 13, 2025 at 2:27 PM
#PortfolioNews | SpliceBio doses the first patient in the Phase 1/2 ASTRA study of SB-007, the first dual AAV #GeneTherapy for #StargardtDisease!
🎯 Showcasing the power of #ProteinSplicing to tackle diseases caused by #LargeGenes mutations.
👉 buff.ly/HvB3bPR
#VC
🎯 Showcasing the power of #ProteinSplicing to tackle diseases caused by #LargeGenes mutations.
👉 buff.ly/HvB3bPR
#VC
#ASGCT2026 is two weeks away — and we have new data to share.
Ascidian will present first-in-human safety data for ACDN-01 in #StargardtDisease, and data demonstrating the potential of our platform across multiple therapeutic areas.
See what's coming ➡️ ascidian-tx.com/wp-content/u...
Ascidian will present first-in-human safety data for ACDN-01 in #StargardtDisease, and data demonstrating the potential of our platform across multiple therapeutic areas.
See what's coming ➡️ ascidian-tx.com/wp-content/u...
April 28, 2026 at 12:22 PM
#ASGCT2026 is two weeks away — and we have new data to share.
Ascidian will present first-in-human safety data for ACDN-01 in #StargardtDisease, and data demonstrating the potential of our platform across multiple therapeutic areas.
See what's coming ➡️ ascidian-tx.com/wp-content/u...
Ascidian will present first-in-human safety data for ACDN-01 in #StargardtDisease, and data demonstrating the potential of our platform across multiple therapeutic areas.
See what's coming ➡️ ascidian-tx.com/wp-content/u...
✨This #BlindnessAwarenessMonth, we’re grateful for voices that catalyze change✨
In 2023, Two Blind Brothers visited Ascidian through our FFB Vision Walk sponsorship, sharing their #StargardtDisease story.
Their words still remind us why we do what we do & why every step with this community matters.
In 2023, Two Blind Brothers visited Ascidian through our FFB Vision Walk sponsorship, sharing their #StargardtDisease story.
Their words still remind us why we do what we do & why every step with this community matters.
October 23, 2025 at 2:06 PM
✨This #BlindnessAwarenessMonth, we’re grateful for voices that catalyze change✨
In 2023, Two Blind Brothers visited Ascidian through our FFB Vision Walk sponsorship, sharing their #StargardtDisease story.
Their words still remind us why we do what we do & why every step with this community matters.
In 2023, Two Blind Brothers visited Ascidian through our FFB Vision Walk sponsorship, sharing their #StargardtDisease story.
Their words still remind us why we do what we do & why every step with this community matters.
#ICYMI, earlier this month Ascidian and Forge Biologics announced a manufacturing partnership to advance ACDN-01, our lead RNA exon editing candidate for #StargardtDisease.
Check out this BioProcess International article to learn more:
tinyurl.com/y6c434mv
Check out this BioProcess International article to learn more:
tinyurl.com/y6c434mv
Ascidian partners with Forge Biologics against Stargardt disease
The companies have entered a manufacturing partnership to advance Ascidian’s lead retinal candidate.
www.bioprocessintl.com
January 29, 2026 at 1:19 PM
#ICYMI, earlier this month Ascidian and Forge Biologics announced a manufacturing partnership to advance ACDN-01, our lead RNA exon editing candidate for #StargardtDisease.
Check out this BioProcess International article to learn more:
tinyurl.com/y6c434mv
Check out this BioProcess International article to learn more:
tinyurl.com/y6c434mv
Murray's Musings | Episode 2
“Urgency is a moral imperative.”
🎥 Our CDO Murray A. Abramson, MD, MPH explains how our #STARPATH prescreening study in #StargardtDisease helps get patients into clinical trials sooner — and why every day matters.
Learn more: www.AscidianClinicalTrials.com
“Urgency is a moral imperative.”
🎥 Our CDO Murray A. Abramson, MD, MPH explains how our #STARPATH prescreening study in #StargardtDisease helps get patients into clinical trials sooner — and why every day matters.
Learn more: www.AscidianClinicalTrials.com
September 21, 2026 at 12:23 PM
Murray's Musings | Episode 2
“Urgency is a moral imperative.”
🎥 Our CDO Murray A. Abramson, MD, MPH explains how our #STARPATH prescreening study in #StargardtDisease helps get patients into clinical trials sooner — and why every day matters.
Learn more: www.AscidianClinicalTrials.com
“Urgency is a moral imperative.”
🎥 Our CDO Murray A. Abramson, MD, MPH explains how our #STARPATH prescreening study in #StargardtDisease helps get patients into clinical trials sooner — and why every day matters.
Learn more: www.AscidianClinicalTrials.com
Once-daily oral gildeuretinol halted disease progression in additional patients with early-stage Stargardt disease, according to positive interim data from the TEASE-3 clinical trial.
🔗 www.hcplive.com/view/gildeur...
#StargardtDisease #RareDisease #Ophthalmology
🔗 www.hcplive.com/view/gildeur...
#StargardtDisease #RareDisease #Ophthalmology
January 11, 2025 at 4:05 AM
Once-daily oral gildeuretinol halted disease progression in additional patients with early-stage Stargardt disease, according to positive interim data from the TEASE-3 clinical trial.
🔗 www.hcplive.com/view/gildeur...
#StargardtDisease #RareDisease #Ophthalmology
🔗 www.hcplive.com/view/gildeur...
#StargardtDisease #RareDisease #Ophthalmology
#StargardtDisease is an inherited retinal disorder leading to progressive vision loss with no current treatment. New in @arvoiovs.bsky.social, read how FPF imaging could be a non-invasive biomarker for detecting early metabolic changes before evident structural damage. bit.ly/4ljvMov
#VisionResearch
#VisionResearch
August 6, 2025 at 5:01 PM
#StargardtDisease is an inherited retinal disorder leading to progressive vision loss with no current treatment. New in @arvoiovs.bsky.social, read how FPF imaging could be a non-invasive biomarker for detecting early metabolic changes before evident structural damage. bit.ly/4ljvMov
#VisionResearch
#VisionResearch
That's a wrap on #ASGCT2026: First-in-human safety data for #ACDN-01 in #StargardtDisease. AI/ML-powered platform advances. Preclinical data in repeat expansion disorders.
Great science, great conversations.
We are thankful for this community and energized for what's next! #RNAExonEditing.
Great science, great conversations.
We are thankful for this community and energized for what's next! #RNAExonEditing.
May 15, 2026 at 10:56 PM
That's a wrap on #ASGCT2026: First-in-human safety data for #ACDN-01 in #StargardtDisease. AI/ML-powered platform advances. Preclinical data in repeat expansion disorders.
Great science, great conversations.
We are thankful for this community and energized for what's next! #RNAExonEditing.
Great science, great conversations.
We are thankful for this community and energized for what's next! #RNAExonEditing.
Translational Gene Therapy Breakthroughs for Inherited and Acquired Blindness
#blindness #RetinitisPigmentosa #StargardtDisease, #UsherSyndrome #LeberCongenitalAmaurosis #LCA #glaucoma #GeographicAtrophy #MacularDegeneration #genetherapy
www.marinbio.com/from-bench-t...
#blindness #RetinitisPigmentosa #StargardtDisease, #UsherSyndrome #LeberCongenitalAmaurosis #LCA #glaucoma #GeographicAtrophy #MacularDegeneration #genetherapy
www.marinbio.com/from-bench-t...
Translational Gene Therapy Breakthroughs for Inherited and Acquired Blindness
Discover advanced gene therapy strategies for blindness at ASGCT 2025, featuring innovative cell based assays and transformative treatments for inherited vision loss.
www.marinbio.com
June 2, 2025 at 2:06 AM
Translational Gene Therapy Breakthroughs for Inherited and Acquired Blindness
#blindness #RetinitisPigmentosa #StargardtDisease, #UsherSyndrome #LeberCongenitalAmaurosis #LCA #glaucoma #GeographicAtrophy #MacularDegeneration #genetherapy
www.marinbio.com/from-bench-t...
#blindness #RetinitisPigmentosa #StargardtDisease, #UsherSyndrome #LeberCongenitalAmaurosis #LCA #glaucoma #GeographicAtrophy #MacularDegeneration #genetherapy
www.marinbio.com/from-bench-t...
#BeliteBio has said the results of the DRAGON trial of its oral therapy for sight-robbing disorder #Stargardtdisease type 1 (STGD1), tinlarebant, could support an FDA filing. #retinaldisease
pharmaphorum.com/news/belite-...
pharmaphorum.com/news/belite-...
Belite plans filing for oral Stargardt drug after phase 3 win
The first therapy for sight-robbing Stargardt disease could be on the way, as Belite Bio's tinlarebant hits the mark in a phase 3 trial.
pharmaphorum.com
December 1, 2025 at 3:02 PM
#BeliteBio has said the results of the DRAGON trial of its oral therapy for sight-robbing disorder #Stargardtdisease type 1 (STGD1), tinlarebant, could support an FDA filing. #retinaldisease
pharmaphorum.com/news/belite-...
pharmaphorum.com/news/belite-...
#TeamAscidian is excited to join The Carroll Center for the Blind Walk for Independence on May 30! 💙
Register to join us: bit.ly/4ukOcun
Be sure to stop by the Ascidian booth to say hi, learn about our #StargardtDisease clinical trials, and grab some swag.
See you there!
Register to join us: bit.ly/4ukOcun
Be sure to stop by the Ascidian booth to say hi, learn about our #StargardtDisease clinical trials, and grab some swag.
See you there!
Walk for Independence - The Carroll Center for the Blind
Join us for the Walk for Independence, an extraordinary community event that supports our mission.
bit.ly
May 21, 2026 at 12:02 PM
#TeamAscidian is excited to join The Carroll Center for the Blind Walk for Independence on May 30! 💙
Register to join us: bit.ly/4ukOcun
Be sure to stop by the Ascidian booth to say hi, learn about our #StargardtDisease clinical trials, and grab some swag.
See you there!
Register to join us: bit.ly/4ukOcun
Be sure to stop by the Ascidian booth to say hi, learn about our #StargardtDisease clinical trials, and grab some swag.
See you there!
This #RareDiseaseMonth, we’re celebrating accessibility that sparks joy.
Bricks for the Blind adapts LEGO instructions so visually impaired builders can create independently — showing that vision loss doesn’t have to mean losing what you love.
Read more: bit.ly/3Z7CViT
#StargardtDisease
Bricks for the Blind adapts LEGO instructions so visually impaired builders can create independently — showing that vision loss doesn’t have to mean losing what you love.
Read more: bit.ly/3Z7CViT
#StargardtDisease
Boston nonprofit creates Braille Lego instructions for builders after Denmark company's limited response - Boston Business Journal
Two years ago, he founded the Boston-area non-profit Bricks for the Blind, which has since adapted over 470 Lego instruction kits that have been downloaded more than 30,000 times.
bit.ly
February 4, 2026 at 1:09 PM
This #RareDiseaseMonth, we’re celebrating accessibility that sparks joy.
Bricks for the Blind adapts LEGO instructions so visually impaired builders can create independently — showing that vision loss doesn’t have to mean losing what you love.
Read more: bit.ly/3Z7CViT
#StargardtDisease
Bricks for the Blind adapts LEGO instructions so visually impaired builders can create independently — showing that vision loss doesn’t have to mean losing what you love.
Read more: bit.ly/3Z7CViT
#StargardtDisease
Why rewrite RNA instead of DNA? Ascidian CSO Robert Bell explains, and shares highlights from our first-in-human safety data for #ACDN-01 in #StargardtDisease. Watch his interview from #ASGCT2026 with Brad Loncar and @biotechtv.bsky.social.
➡️ www.biotechtv.com/post/asgct-2...
➡️ www.biotechtv.com/post/asgct-2...
ASGCT 2026: Ascidian Therapeutics is presenting initial human safety data from its RNA exon editing platform in a Stargardt disease trial
CSO Robert Bell describes the advantages of RNA exon editing he sees over DNA editing, and walks us through the safety data. With that in hand, which was in adult patients, the company is moving forwa...
www.biotechtv.com
May 14, 2026 at 2:12 PM
Why rewrite RNA instead of DNA? Ascidian CSO Robert Bell explains, and shares highlights from our first-in-human safety data for #ACDN-01 in #StargardtDisease. Watch his interview from #ASGCT2026 with Brad Loncar and @biotechtv.bsky.social.
➡️ www.biotechtv.com/post/asgct-2...
➡️ www.biotechtv.com/post/asgct-2...
Michael Owen opens up about son's rare eye condition and hopes for future business partnership #MichaelOwen #StargardtDisease #FamilyBonding
http://opr.news/6f44295f260820en_gb?share_from=opera_social&country=gb&language=en
Tap to read more 👇
Download App Now ➡️ https://opr.as/share
http://opr.news/6f44295f260820en_gb?share_from=opera_social&country=gb&language=en
Tap to read more 👇
Download App Now ➡️ https://opr.as/share
Michael Owen breaks down over son's heartbreaking health issue that is a 'ticking time bomb'
Michael Owen has opened up with an emotional interview about his son
(Image: Instagram)
Michael Owen
opr.news
August 21, 2026 at 10:00 AM
Michael Owen opens up about son's rare eye condition and hopes for future business partnership #MichaelOwen #StargardtDisease #FamilyBonding
http://opr.news/6f44295f260820en_gb?share_from=opera_social&country=gb&language=en
Tap to read more 👇
Download App Now ➡️ https://opr.as/share
http://opr.news/6f44295f260820en_gb?share_from=opera_social&country=gb&language=en
Tap to read more 👇
Download App Now ➡️ https://opr.as/share
We’re presenting new preclinical data at #ARVO2026 on our investigational RNAi therapy, CITY-RBP4, for #StargardtDisease. Data show potent, durable RBP4 silencing and reduced toxic retinoids. Learn more: www.businesswire.com/news/home/20...
May 6, 2026 at 11:39 AM
We’re presenting new preclinical data at #ARVO2026 on our investigational RNAi therapy, CITY-RBP4, for #StargardtDisease. Data show potent, durable RBP4 silencing and reduced toxic retinoids. Learn more: www.businesswire.com/news/home/20...